Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32667230 | 0.84 | CHRNB2 (0.41) | CHRNB2CHRNA4 | |
| SCHEMBL28947625 | 0.81 | CHRNB2 (0.41) | CHRNB2CHRNA4 | |
| SCHEMBL21601261 | 0.80 | IGLV6-57 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL21601259 | 0.80 | IGLV6-57 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL20539460 | 0.79 | CHRNB2 (0.40) | CHRNB2CHRNA4 | |
| SCHEMBL2608829 | 0.78 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL1228991 | 0.78 | APP (0.42) | CHRNB2CHRNA4CYP2C9 | |
| SCHEMBL31038327 | 0.78 | NQO1 (0.54) | CHRNB2CHRNA4KDM4EMAPT | |
| SCHEMBL165740 | 0.78 | NQO1 (0.54) | CHRNB2CHRNA4KDM4EMAPT | |
| SCHEMBL11951666 | 0.77 | HPGD (0.41) | KDM4EALDH1A1POLBMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055839-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-02-20 | — | — | US | disclosed |
| US-20200055839-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-02-20 | — | — | US | disclosed |
| EP-3565809-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ViiV Healthcare UK (No.5) Limited (GB) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018127800-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018127800-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-07-12 | — | — | WO | disclosed |
| EP-2611771-B1 | SUBSTITUTED HETEROARYL- AND ARYLALKYNYL BENZENE DERIVATIVES AS ACC-INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-11-23 | — | — | EP | disclosed |
| EP-2588451-B1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-30 | — | — | EP | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-8877741-B2 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| WO-2012028676-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012001107-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| CN-101821264-A | Pyridine derivatives useful as glucokinase activators | MERCK PATENT GMBH | 2010-09-01 | — | — | CN | disclosed |
| US-20100216794-A1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-26 | — | — | US | disclosed |
| EP-2195312-A1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009046784-A1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | P2RX5, P2RX3, ABCG2 | CHRNB2 3806/4885CHRNA4 2534/4885KDM4E 2840/4885 |
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | ABCG2, PGA5, PDE6G | CHRNB2 4606/4885CHRNA4 4638/4885KDM4E 4276/4885 |
| US-20200055839-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | TYMP, TYMS, DUT | CHRNB2 4108/4885CHRNA4 3865/4885KDM4E 1707/4885 |
| US-20100216794-A1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | HK1, GCKR, GCK | CHRNB2 2846/4885CHRNA4 1696/4885KDM4E 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.